6 March 2023 Latest news on the development of a prophylactic treatment for FNAIT. NEW HAVEN, Conn.–(BUSINESS WIRE)–Mar. 6, 2023– Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects. Share Related postsJune 4, 2024May 2024 – Doctor Thijs W de Vos receives prize for the best dissertation 2023-24 within the field, at the NVB-TRIP Symposium!Read moreMay 14, 2024Care Design New York – Member Spotlight – Meet Chris!!!Read moreApril 25, 202410 April 2024-FNAIT Collaboration Agreement between Momenta Pharmaceuticals, Inc., a Johnson & Johnson Company, and Rallybio IPA, LLCRead more